SOS1-IN-2 |
| Catalog No.GC37667 |
SOS1-IN-2 (composé I-6) est un inhibiteur oral, très puissant et sélectif de l'interaction entre KRAS et Son of Sevenless 1 (SOS1) avec une IC50 de 6 nM. SOS1-IN-2 réduit puissamment la formation de KRAS chargés de GTP et inhibe la signalisation de la voie MAPK. SOS1-IN-2 a une activité anticancéreuse.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2230836-55-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SOS1-IN-2 is a Son of Sevenless 1 (SOS1) inhibitor extracted from patent WO2018115380A1, compound I-6, and it has an IC50 of 6 nM[1]. IC50: 6 nM (SOS1)[1]
[1]. Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1.
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *